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Introduction
Arrhythmogenic right ventricular cardiomyo-
pathy (ARVC) is a genetically determined myocar-
dial disease resulting in fibrofatty degeneration of
myocardium. Most known mutations associated
with the development of this disease affect genes
responsible for coding information on desmosomal
proteins. The primary function of these proteins is
to form intercellular junctions. Disruption of desmo-
somes invariably leads to cell death, and resulting
tissue remodeling impairs electrical conduction cre-
ating conditions for re-entry. The natural history of
ARVC involves three clinical stages [1, 2]:
— initial asymptomatic phase;
— focal structural changes with electrical insta-
bility;
— global impairment of contractility with symp-
tomatic heart failure.
The incidence of ARVC is estimated at 1:5,000
to 1:10,000. The disease usually manifests at young
age, mostly in the second or third decade of life.
Patients present with ventricular arrhythmia fol-
lowed later by symptoms of heart failure. Cardiac
arrest may also be an initial presentation. Studies
show that ARVC is one of the most common caus-
es of sudden cardiac death in young, apparently
healthy people, accounting for 5–11% of sudden
deaths in subjects below 35 years of age [3]. The
disease is more common among men, although gen-
der seems not to affect the risk of sudden cardiac
death. Most fatal cases occur in the fourth decade
of life (mean age 35.5 ± 12.0 years), and yearly
mortality rate is about 2.8%, with 1/3 of deaths
occuring suddenly and the remaining 2/3 due to ad-
vanced heart failure [4].
ARVC is also one of the most common causes
of sudden deaths during sport participation. Accord-
ing to some authors, up to 22% of sudden deaths
among athletes may be related to this form of car-
diomyopathy. Studies performed in the 1980s in
a large population of competitive athletes in Italy
showed that intensive physicial training is associa-
ted with a 5-fold increase in risk of a sudden car-
diac death.
Sudden deaths in ARVC usually occur during
daily life activities (76% of cases), stressful situa-
tions (10%) or in the perioperative period (10%).
Only 3.5% of deaths occur during intensive physi-
cal activity, which is likely related to a limited
number of subjects participating in competitive
sports [3].
Evaluation of risk
Evaluation of risk factors of sudden cardiac
death in ARVC should include [1, 3]:
— previous episodes of cardiac arrest;
— syncope;
— a history of sudden cardiac death in a family
member below 35 years of age;
— extensive right ventricular damage;
— concomitant left ventricular dysfunction;
— induction of ventricular tachycardia during pro-
grammed electrical stimulation;
— wide QRS complexes in V1–V3, QRS disper-
sion, and the presence of epsilon wave (a mar-
ker of ventricular late potentials).
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How to identify patients at highest risk of sud-
den death? According to most authors, the strong-
est risk factor is history of previous cardiac arrest
or syncope [3]. Opinions on the relative importance
of other risk factors are discordant. Long-term data
presented by a group of French authors indicate
high risk of sudden cardiac death in patients with
severe righ ventricular dysfunction and symptomat-
ic right-sided heart failure, as well as in patients
with concomitant left ventricular dysfunction and
recurrent sustained ventricular tachycardia [2].
Some authors suggest that apart from clinical symp-
toms of heart failure, additional electrocardiographic
(ECG) criteria should also be taken into account,
such as the presence of negative T waves in leads
V4–V6. Another risk factor of sudden cardiac death
in ARVC is QRS dyspersion ≥ 40 ms (specificity
90%, sensitivity 77%). The risk of sudden death
seems to be particularly high in patients with QRS
dyspersion ≥ 50 ms, negative T waves in precor-
dial leads, and a history of syncope [3, 5].
Analysis of risk factors may be supported with
data collected from patients with an implanted car-
dioverter-defibrillator (ICD). These data show that
appropriate ICD therapy was most common in pa-
tients with such risk factors as severe right ven-
tricular dysfunction, previous cardiac arrest, histo-
ry of hemodynamically unstable ventricular tachy-
cardia, young age, left ventricular dysfunction, and
induction of a rapid ventricular tachycardia with
programmed electrical stimulation during the elec-
trophysiological study [6–9]. Of note, the electro-
physiological study itself has little prognostic val-
ue in ARVC, as both positive and negative predic-
tive values for the occurrence of malignant
arrhythmia do not exceed 50%. This has been re-
flected in the European Society of Cardiology (ESC)
guidelines rating the performance of the electro-
physiological study in patients with ARVC as class
IIb recommendation (level of evidence: C).
Very useful practical clues may be obtained
from the analysis of ECGs recorded during arrhyth-
mia. Most typically, ventricular tachycardia with the
left bundle branch block morphology is seen, which
is not a risk factor of sudden cardiac death in he-
modynamically stable patient with ARVC.
Currently, risk stratification in ARVC is often
supplemented by the findings of genetic studies.
Variants of the disease associated with significant-
ly higher risk of sudden deaths have beeen identi-
fied, such as Naxos disease, which is a recessive
form of ARVC occuring predominantly in inhabi-
tants of this Greek island. Another variant of ARVC,
observed in inhabitants of Newfoundland, is asso-
ciated with almost 7-fold increase in risk for male
carriers of the mutation in comparison to the female
carriers. The most common genetic variants of
ARVC in Europe and in the United States result
from autosomal dominant mutations of genes for
plakophillin-2, desmoplakin, and desmoglein-2,
seen in 11–50%, 6–16%, and 10% of patients, re-
spectively. In Poland, the most prevalent mutations
occur in plakophillin-2 gene and are associated with
a significantly worse prognosis [4].
How to decrease the risk
of sudden cardiac death?
The most important advice for patients with
ARVC is to refrain from competitive sports. Experi-
mental studies showed that intensive exercise leads
to expression of the disease. Chronically increased
right ventricular volume load in patients with
defective desmosomal proteins results in disruption
of abnormal intercellular junctions, which initiates
the cascade of apoptotic processes leading to
remodelling of myocardium and predisposing to
cardiac arrhythmias in the mechanism of re-entry.
In addition to this unfavourable effect on myo-
cardial remodelling, intensive exercise in patients
with ARVC may also directly trigger malignant ar-
rhythmia, especially when extreme effort is accom-
panied by stress, such as during participation in
competitive sports. In such conditions, disruption
of abnormal intercellular junctions ensues, leading
to focal cardiomyocyte necrosis and, when elevat-
ed catecholamine levels are present, development
of late afterdepolarizations that may result in ven-
tricular fibrillation. This mechanism may also oc-
cur in low-risk patients, even in an asymptomatic
stage of the disease.
Antiarrhythmic pharmacotherapy in patients
with ARVC is quite effective. Good treatment ef-
fects are obtained in about 65% of patients, and
partial improvement is seen in additional 13% of
patients. The most effective drug (in nearly 70% of
cases) is sotalol, usually administered in large dos-
es (ranging from 320 to 640 mg/day). Low-risk pa-
tients may be treated with beta-blockers, especial-
ly if arrhythmia occurs mainly during daily or phy-
sical activities [4]. In contrast, werapamil may be
indicated in cases of arrhythmias occurring at rest,
although this drug is effective only in about 44% of
patients. Significant right ventricular dysfunction is
an independent predictive factor for the ineffective-
ness of antiarrhythmic pharmacoterapy. In patients
who do not respond to pharmacoterapy, as well as
in patients with recurrent ventricular tachycardia
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despite optimal therapy, ablation of the arrhythmic
substrate should be considered (class II recommen-
dation in the ESC guidelines, level of evidence: C).
Which patients should
be treated with an ICD?
High-risk patients should be protected from
sudden cardiac death by ICD implantation. This
group primarily includes patients after a cardiac
arrest or syncope due to ventricular tachycardia,
and patients with a history of unexplained syncope
if arrhythmia cannot be excluded as the cause of this
syncope. In the ESC guidelines, ICD implantation
in patients with documented sustained ventricular
tachycardia and/or ventricular fibrillation who re-
ceive optimal pharmacotherapy, if their expected
survival in a good clinical condition exceeds one year,
is a class I recommendation (level of evidence: B).
The authors of the guidelines acknowledge that no
large randomized clinical trials in patients with
ARVC have been published to support this recom-
mendation, but the clinical situation in these pa-
tients is thought to be very similar to that of patients
after a myocardial infarction, in whom benefits of
prophylactic ICD implantation have been well es-
tablished.
In patients with severe form of ARVC (left ven-
tricular involvement, sudden cardiac death in at
least one family member, or unexplained syncope
if ventricular tachycardia or ventricular fibrillation
cannot be excluded as the cause of this syncope)
fulfilling similar general requirements as stated
above, e.g. expected survival exceeding one year,
ICD implantation is a class IIa recommendation (le-
vel of evidence: C).
Low-risk patients, particularly with hemody-
namically stable monomorphic ventricular tachycar-
dia, have no indications for ICD implantation and
should be treated with pharmacotherapy or ablation.
The same applies to patients in whom ICD implan-
tation is indicated but not possible for some reasons
(class IIa recommendation, level of evidence: C).
Data from patients with ARVC and implanted
ICD show that appropriate ICD therapy accounts
for 48–78% of all ICD interventions, including life-
saving interventions in 24–50% of cases. If one con-
siders only prophylactic ICD implantations (prima-
ry prevention of sudden cardiac death), results are
very similar, with appropriate ICD interventions in
about 70% of patients, and life-saving interventions
reported in about 30% of cases.
Despite these good outcomes, the decision
about ICD implantation should always result from
careful consideration. Reassuringly, only about
15–30% of all ICD interventions are inappropriate,
which usually is triggered either by an arrhythmia that
is not a life-threatening one (most commonly atrial fi-
brillation or supraventricular tachycardia) or results
from lead dysfunction or displacement. ICD shocks
may be a cause of serious discomfort for the patient,
leading even to clinical depression. Moreover, lead im-
plantation in patients with ARVC may be associated
with disease-specific problems, including [7]:
— risk of perforation of the thin-walled right ven-
tricle;
— difficulties in accurate lead placement related
to low R wave amplitude;
— potentially increased pacing and defibrillation
thresholds;
— sensing and pacing abnormalities and increased
defibrillation threshold due to progression of
the disease.
Should dramatic complications ensue, it may be
necessary to implant subcutaneous defibrillating
leads or refer a patient for urgent heart transplan-
tation. Fortunately, such scenarios are very rare.
Most patients tolerate ICD implantation well, and
frequent ICD shocks may be prevented by beta-
-blockers. In case of insufficient effectiveness of
antiarrhythmic treatment, patient’s referral for ra-
diofrequency ablation should always be considered.
Summary
Evaluation of the risk of sudden cardiac death
and assessment of indications for ICD implantation
should be performed individually in each patient,
taking into account all aspects of the clinical picture
and the experience of the managing physician.
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